MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Medical Tourism
Compare and save on surgery

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Teveten HCT

Teveten HCT (eprosartan mesylate/hydrochlorothiazide)


Company: Unimed Pharmaceuticals
Approval Status: Approved November 2001
Treatment for: Hypertension
Areas: Cardiology/Vascular Diseases
Possible similar drugs: Teveten

| General Information | Side Effects | Mechanism of Action | Additional Information |


General Information

Other Useful Resources

Teveten HCT, a combination of eprosartan mesylate and hydrochlorothiazide, has been approved by the FDA for the treatment of hypertension (high blood pressure). Eprosartan mesylate works by blocking the angiotensin II receptor. The hormone angiotensin II plays a role in hypertension by causing blood vessels to constrict, which raises blood pressure. By blocking the effects of angiotensin II, eprosartan mesylate prevents this pressure increase. Hydrochlorothiazide is also an anti-hypertensive compound; however, the way in which thiazides produce this effect is unknown.

According to the National Heart, Lung, and Blood Institute, it is estimated that one in every four American adults has hypertension. Hypertension can be defined as a sustained elevation of the force of blood against the walls of the arteries. The first line of treatment for hypertension is changing unhealthy lifestyle habits; if this is not sufficient, blood pressure medications may be utilized.



< back to top

Side Effects

Side effects reported with eprosartan mesylate use in clinical trials include:

  • Upper respiratory tract infection
  • Rhinitis
  • Pharyngitis (inflammation of the pharynx)
  • Cough
  • Fatigue
  • Abdominal pain
  • Joint pain

< back to top

Mechanism of Action

Angiotensin II, a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Angiotensin II also stimulates aldosterone synthesis and secretion by the adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). (from Teveten Prescribing Information)



< back to top

Additional Information

For more information on hypertension, please visit the National Heart, Lung, and Blood Institute.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.